AR100920A1 - Composiciones antimicrobianas con agentes efervescentes, método - Google Patents

Composiciones antimicrobianas con agentes efervescentes, método

Info

Publication number
AR100920A1
AR100920A1 ARP150101976A ARP150101976A AR100920A1 AR 100920 A1 AR100920 A1 AR 100920A1 AR P150101976 A ARP150101976 A AR P150101976A AR P150101976 A ARP150101976 A AR P150101976A AR 100920 A1 AR100920 A1 AR 100920A1
Authority
AR
Argentina
Prior art keywords
efervescent
agents
pharmaceutical composition
antimicrobial compositions
ester
Prior art date
Application number
ARP150101976A
Other languages
English (en)
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54868661&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR100920(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of AR100920A1 publication Critical patent/AR100920A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica que comprende (a) un derivado de ácido quinolona carboxílico o su sal o éster farmacéuticamente aceptable; y (b) un agente efervescente. Reivindicación 4: La composición farmacéutica de la reivindicación 1, donde dicho derivado de ácido quinolona carboxílico corresponde al compuesto de fórmula (1) o su sal o éster farmacéuticamente aceptable. Reivindicación 14: La composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 13, donde el agente efervescente comprende una mezcla de bicarbonato sódico, dihidrógeno fosfato sódico y ácido cítrico.
ARP150101976A 2014-06-20 2015-06-19 Composiciones antimicrobianas con agentes efervescentes, método AR100920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462014786P 2014-06-20 2014-06-20

Publications (1)

Publication Number Publication Date
AR100920A1 true AR100920A1 (es) 2016-11-09

Family

ID=54868661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101976A AR100920A1 (es) 2014-06-20 2015-06-19 Composiciones antimicrobianas con agentes efervescentes, método

Country Status (31)

Country Link
US (2) US20150366857A1 (es)
EP (3) EP3581180B1 (es)
JP (2) JP6995479B2 (es)
CN (2) CN114831955B (es)
AR (1) AR100920A1 (es)
AU (3) AU2015276954B2 (es)
BR (1) BR112016029761B1 (es)
CA (1) CA2952950C (es)
CL (2) CL2016003273A1 (es)
CR (2) CR20160592A (es)
CY (2) CY1121995T1 (es)
DK (2) DK3157510T3 (es)
EA (1) EA034152B1 (es)
EC (1) ECSP16095540A (es)
ES (2) ES2732865T3 (es)
HR (2) HRP20211685T1 (es)
HU (2) HUE056298T2 (es)
IL (1) IL249622A0 (es)
LT (2) LT3581180T (es)
MX (2) MX368940B (es)
PE (2) PE20210927A1 (es)
PH (1) PH12016502548A1 (es)
PL (2) PL3157510T3 (es)
PT (2) PT3581180T (es)
RS (2) RS62538B1 (es)
SI (2) SI3157510T1 (es)
SV (1) SV2016005349A (es)
TR (1) TR201909417T4 (es)
TW (2) TWI705814B (es)
UY (1) UY36184A (es)
WO (1) WO2015196027A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022240897A1 (en) * 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194617A (en) * 1988-12-17 1993-03-16 Meiji Seika Kaisha, Ltd. 2,3-disubstituted-4-hydroxyquinoline derivatives
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
EP0992501B1 (en) 1995-09-22 2002-08-28 Wakunaga Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives as antibacterial agents
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
EA004443B1 (ru) 1998-09-14 2004-04-29 Рэнбакси Лабораториз Лимитед Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день
US6187317B1 (en) * 1999-07-14 2001-02-13 Judith Taylor Natural anti-diarrheal composition and method
US6414036B1 (en) * 1999-09-01 2002-07-02 Van Beek Global/Ninkov Llc Composition for treatment of infections of humans and animals
JP2005097116A (ja) 1999-11-11 2005-04-14 Wakunaga Pharmaceut Co Ltd キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
EP1789392A2 (en) 2004-07-30 2007-05-30 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
WO2006042034A2 (en) 2004-10-08 2006-04-20 Abbott Laboratories Salt and crystalline forms thereof of a drug
NZ555501A (en) * 2004-11-24 2010-01-29 Medpointe Healthcare Inc Compositions comprising azelastine and methods of use thereof
PT1868581E (pt) 2005-04-11 2012-06-22 Abbott Lab Composições farmacêuticas que possuem perfis de dissolução melhorados para fármacos pouco solúveis
EP1745775B1 (en) 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
US7611739B2 (en) 2006-01-06 2009-11-03 Amerilab Technologies, Inc. Method of using guava extract and composition including guava extract
US7892447B2 (en) * 2006-08-11 2011-02-22 Aqua Resources Corporation Nanoplatelet metal hydroxides and methods of preparing same
CN1943561A (zh) * 2006-08-23 2007-04-11 北京阜康仁生物制药科技有限公司 普卢利沙星口腔崩解片及其制备方法
HUE046465T2 (hu) 2006-12-22 2020-03-30 Ironwood Pharmaceuticals Inc Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére
NZ580972A (en) * 2007-06-04 2012-02-24 Egalet Ltd Controlled release pharmaceutical compositions for prolonged effect
MY194407A (en) * 2008-11-15 2022-11-30 Melinta Subsidiary Corp Antimicrobial Compositions
WO2010096551A2 (en) * 2009-02-18 2010-08-26 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions
GB201020076D0 (en) * 2010-11-26 2011-01-12 Liverpool School Tropical Medicine Antimalarial compounds
ES2637113T3 (es) * 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
BR112013017985B1 (pt) * 2011-01-14 2021-06-29 Spero Therapeutics Inc. Formas sólidas de inibidor de girase (r)-1-etil-3-[6-flúor-5-[2-(1-hidróxi-1-metil-etil)pirimidin- 5-il]-7-(tetra-hidrofuran-2-il)-1h-benzimidazol-2-il]ureia, seu sal de ácido clorídrico, método de preparação das mesmas e composição farmacêutica que os compreende
JP2013034468A (ja) * 2011-08-10 2013-02-21 Nisshin Sugar Mfg Co Ltd 発泡成型甘味料
WO2013090893A1 (en) * 2011-12-16 2013-06-20 Celanese Eva Performance Polymers, Inc. Gastroretentive controlled release vehicles that include ethylene copolymers, ethyl celluloses, and/or thermpoplastic polyurethanes
CN102697751A (zh) * 2012-05-30 2012-10-03 河南牧翔动物药业有限公司 一种畜禽专用恩诺沙星泡腾分散片及其制备方法

Also Published As

Publication number Publication date
PL3157510T3 (pl) 2019-12-31
RS59064B1 (sr) 2019-08-30
NZ727638A (en) 2023-08-25
CA2952950C (en) 2023-11-14
MX368940B (es) 2019-10-21
EP3157510A1 (en) 2017-04-26
AU2015276954A1 (en) 2017-01-12
CN114831955B (zh) 2024-03-12
SI3157510T1 (sl) 2019-09-30
CN106572982B9 (zh) 2022-07-08
BR112016029761A2 (pt) 2017-08-22
DK3581180T3 (da) 2021-11-08
JP2020183415A (ja) 2020-11-12
CR20160592A (es) 2017-02-21
TW201625249A (zh) 2016-07-16
EP3581180A1 (en) 2019-12-18
ES2897576T3 (es) 2022-03-01
PL3581180T3 (pl) 2022-02-07
AU2020256457B2 (en) 2021-09-30
RS62538B1 (sr) 2021-12-31
DK3157510T3 (da) 2019-07-01
SI3581180T1 (sl) 2021-12-31
UY36184A (es) 2016-01-29
US20150366857A1 (en) 2015-12-24
MX2019012608A (es) 2019-12-02
CL2020003153A1 (es) 2021-06-25
CA2952950A1 (en) 2015-12-23
EP3157510A4 (en) 2018-02-21
ES2732865T3 (es) 2019-11-26
CY1121995T1 (el) 2020-10-14
EA201692532A1 (ru) 2017-05-31
EP3919057A1 (en) 2021-12-08
EA034152B1 (ru) 2020-01-09
AU2015276954B2 (en) 2020-07-23
JP6995479B2 (ja) 2022-01-14
CY1125395T1 (el) 2023-03-24
HRP20191133T1 (hr) 2019-09-20
PT3581180T (pt) 2021-11-09
SV2016005349A (es) 2017-08-31
ECSP16095540A (es) 2017-03-31
CN106572982A (zh) 2017-04-19
HRP20211685T1 (hr) 2022-02-04
AU2021286284A1 (en) 2022-01-06
AU2021286284B2 (en) 2024-02-29
MX2016017350A (es) 2017-04-06
CR20200565A (es) 2021-01-14
HUE056298T2 (hu) 2022-02-28
HUE044764T2 (hu) 2019-11-28
PE20210927A1 (es) 2021-05-19
IL249622A0 (en) 2017-02-28
TWI732337B (zh) 2021-07-01
EP3157510B1 (en) 2019-03-27
EP3581180B1 (en) 2021-08-04
AU2020256457A1 (en) 2020-11-12
CN106572982B (zh) 2022-06-03
TWI705814B (zh) 2020-10-01
CN114831955A (zh) 2022-08-02
JP7149991B2 (ja) 2022-10-07
BR112016029761B1 (pt) 2023-03-07
WO2015196027A1 (en) 2015-12-23
CL2016003273A1 (es) 2017-08-04
JP2017518349A (ja) 2017-07-06
US20200237744A1 (en) 2020-07-30
BR112016029761A8 (pt) 2021-06-29
LT3581180T (lt) 2021-12-27
TW202005650A (zh) 2020-02-01
PT3157510T (pt) 2019-06-21
PE20170304A1 (es) 2017-04-19
TR201909417T4 (tr) 2019-07-22
LT3157510T (lt) 2019-09-25
PH12016502548A1 (en) 2017-04-10

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
PH12016500024A1 (en) Bromodomain inhibitor
BR112018003212A2 (pt) diacereína ou seus análogos para inibir a expressão de asc, expressão de nlrp3 e / ou formação de complexo inflamassoma nlrp3
PE20142314A1 (es) Composiciones intranasales de dexmedetomidina y metodos de uso de ellas
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
PE20150199A1 (es) Composiciones farmaceuticas y tratamiento de mastitis
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
DOP2017000307A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma.
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
WO2016038521A8 (en) Pharmaceutical compositions of liraglutide
MX2019012952A (es) Composiciones parasiticidas que comprenden derivados de indol, metodos y usos de los mismos.
BR112017023164A2 (pt) composto, e, método de prevenir e/ou tratar a esteato-hepatite não alcoólica em um indivíduo em necessidade do mesmo
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA201401160A1 (ru) Паразитицидные композиции, содержащие производные бензимидазола, их способы получения и применения
PH12017502319A1 (en) Injectable pharmaceutical formulations of lefamulin
AR100920A1 (es) Composiciones antimicrobianas con agentes efervescentes, método

Legal Events

Date Code Title Description
FB Suspension of granting procedure